|

Lutetium Lu 177 Vipivotide Tetraxetan Clinical Trials

7 actively recruiting trials across 6 locations

Also known as: 177Lu-PSMA-617, 177Lu-labeled PSMA-617, AAA 617, AAA-617, AAA617, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN, Lu177-PSMA-617, Lutetium Lu 177-PSMA-617, Lutetium-177-PSMA-617, Pluvicto

Los Angeles, California2 trials

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

UCLA / Jonsson Comprehensive Cancer Center

Phase 2
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

Tucson, Arizona1 trial

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Banner University Medical Center - Tucson

Phase 2

Duarte, California1 trial

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

City of Hope Medical Center

Phase 1

San Francisco, California1 trial

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

University of California San Francisco

Phase 2

Rochester, Minnesota1 trial

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Mayo Clinic in Rochester

Phase 2

Seattle, Washington1 trial

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.